Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Company Overview - Syndax Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel cancer therapies, leveraging a targeted pipeline strategy for high-need oncology indications supported by strategic collaborations and licensing agreements [5][6] - As of the latest data, the company's stock price is $24.23, with a market capitalization of $2.1 billion and total revenue of $172.4 million over the trailing twelve months (TTM) [4][5] - The company reported a net income loss of $285.4 million (TTM), indicating ongoing cash burn due to high operating expenses related to research and development (R&D) and commercialization [4][9] Recent Transactions - Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals, valued at approximately $8.18 million, during the fourth quarter of 2025, reducing its position to 10.81% of reportable 13F assets under management [2][5] - Following the sale, the value of Kynam's Syndax position increased by $38.07 million, reflecting both trading and share price movements [2] Performance Metrics - Syndax's stock has surged over 72% in the past year, significantly outperforming the S&P 500's approximate 15% gain during the same period [5] - The company generated about $172 million in total revenue last year, with approximately $124.8 million coming from its recently launched therapies, including Revuforj, and additional contributions from its Niktimvo collaboration [8] Investment Implications - The transaction by Kynam Capital Management suggests a strategic adjustment rather than a complete exit, as the remaining stake still represents a significant portion of their assets [10] - The ongoing tension between growth and profitability is evident, as the company continues to invest heavily in R&D while facing substantial net losses [9]